SARS-CoV-2 ORF6 disrupts nucleocytoplasmic trafficking to advance viral replication
2022 · Communications Biology · 61 citations
https://doi.org/10.1038/s42003-022-03427-4
T
Tatsuya Suzuki
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
146
Papers
2.1K
Citations
24
h-index
56
i10-index
Tatsuya Suzuki is an academic researcher from Taiho Pharmaceutical (Japan). The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & Glycosylation and Glycoproteins Research & COVID-19 Clinical Research Studies. The author has an h-index of 24, co-authored 125 publications.
ORCID: 0000-0002-1437-2273Papers by this author
worksAn inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models
2023 · Science Translational Medicine · 38 citations
https://doi.org/10.1126/scitranslmed.adi2623
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
2023 · Nature Cancer · 32 citations
https://doi.org/10.1038/s43018-023-00630-y
Identification of Functionally Important Residues of the Silkmoth Pheromone Biosynthesis-activating Neuropeptide Receptor, an Insect Ortholog of the Vertebrate Neuromedin U Receptor
2014 · Journal of Biological Chemistry · 22 citations
https://doi.org/10.1074/jbc.m113.488999
Stimulation of interferon-β responses by aberrant SARS-CoV-2 small viral RNAs acting as retinoic acid-inducible gene-I agonists
2022 · iScience · 10 citations
https://doi.org/10.1016/j.isci.2022.105742
Supramolecular tholos-like architecture constituted by archaeal proteins without functional annotation
2020 · Scientific Reports · 9 citations
https://doi.org/10.1038/s41598-020-58371-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat